Precision Medicine for NSCLC in the Era of Immunotherapy: New Biomarkers to Select the Most Suitable Treatment or the Most Suitable Patient.
NSCLC
PD-L1
POLE
PTEN inactivation
STK11
T-Cell clonality
biomarker
immune checkpoint inhibitor
tumor mutational burden
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
30 Apr 2020
30 Apr 2020
Historique:
received:
31
03
2020
revised:
20
04
2020
accepted:
27
04
2020
entrez:
6
5
2020
pubmed:
6
5
2020
medline:
6
5
2020
Statut:
epublish
Résumé
In recent years, the evolution of treatments has made it possible to significantly improve the outcomes of patients with non-small cell lung cancer (NSCLC). In particular, while molecular targeted therapies are effective in specific patient sub-groups, immune checkpoint inhibitors (ICIs) have greatly influenced the outcomes of a large proportion of NSCLC patients. While nivolumab activity was initially assessed irrespective of predictive biomarkers, subsequent pivotal studies involving other PD-1/PD-L1 inhibitors in pre-treated advanced NSCLC (atezolizumab within the OAK study and pembrolizumab in the Keynote 010 study) reported the first correlations between clinical outcomes and PD-L1 expression. However, PD-L1 could not be sufficient on its own to select patients who may benefit from immunotherapy. Many studies have tried to discover more precise markers that are derived from tumor tissue or from peripheral blood. This review aims to analyze any characteristics of the immunogram that could be used as a predictive biomarker for response to ICIs. Furthermore, we describe the most important genetic alteration that might predict the activity of immunotherapy.
Identifiants
pubmed: 32365882
pii: cancers12051125
doi: 10.3390/cancers12051125
pmc: PMC7281184
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Proc Natl Acad Sci U S A. 2016 Oct 18;113(42):11919-11924
pubmed: 27698113
Lung Cancer. 2019 Apr;130:50-58
pubmed: 30885352
N Engl J Med. 2018 Jun 14;378(24):2288-2301
pubmed: 29863955
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Expert Rev Mol Diagn. 2019 Dec;19(12):1099-1108
pubmed: 31608732
J Clin Oncol. 2017 Dec 10;35(35):3924-3933
pubmed: 29023213
Nat Commun. 2020 Jan 30;11(1):603
pubmed: 32001676
J Clin Oncol. 2004 Jul 15;22(14):2954-63
pubmed: 15254063
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
J Immunother Cancer. 2018 Jun 22;6(1):63
pubmed: 29929551
Clin Cancer Res. 2019 Mar 1;25(5):1564-1573
pubmed: 30442684
Front Immunol. 2019 Jun 18;10:1336
pubmed: 31275310
Mod Pathol. 2017 Apr;30(4):530-538
pubmed: 28059094
Oncogene. 2016 Jun 16;35(24):3209-16
pubmed: 26477306
Nat Genet. 2013 Feb;45(2):136-44
pubmed: 23263490
J Clin Invest. 2017 Aug 1;127(8):2930-2940
pubmed: 28650338
Cancer Discov. 2018 Jul;8(7):822-835
pubmed: 29773717
Sci Rep. 2019 Jan 14;9(1):114
pubmed: 30643180
Eur J Cancer. 2017 Oct;84:212-218
pubmed: 28826074
JAMA Oncol. 2019 May 1;5(5):696-702
pubmed: 30816954
Cancer Res. 2016 Mar 1;76(5):999-1008
pubmed: 26833127
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Drug Discov Today. 2017 Jun;22(6):927-936
pubmed: 28288782
J Thorac Oncol. 2017 Feb;12(2):208-222
pubmed: 27913228
Ann Surg Oncol. 2013 Apr;20(4):1381-8
pubmed: 23208128
Lancet. 2016 Apr 9;387(10027):1540-1550
pubmed: 26712084
JAMA Oncol. 2019 Aug 15;:
pubmed: 31415061
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
JCO Precis Oncol. 2019;3:
pubmed: 31428721
Lung Cancer. 2018 Jun;120:108-112
pubmed: 29748004
Clin Lung Cancer. 2018 Sep;19(5):426-434.e1
pubmed: 29803574
Science. 1997 Mar 28;275(5308):1943-7
pubmed: 9072974
Clin Cancer Res. 2014 May 1;20(9):2424-32
pubmed: 24583799
J Immunother Cancer. 2015 Jun 16;3:23
pubmed: 26085931
N Engl J Med. 2018 Nov 22;379(21):2040-2051
pubmed: 30280635
Br J Cancer. 2018 Jan;118(2):e5
pubmed: 29315291
J Mol Diagn. 2018 Jul;20(4):550-564
pubmed: 29787863
Cell Physiol Biochem. 2015;37(4):1560-71
pubmed: 26513143
Cancers (Basel). 2019 Aug 09;11(8):
pubmed: 31404976
Ann Thorac Surg. 2009 Feb;87(2):365-71; discussion 371-2
pubmed: 19161739
J Immunol Res. 2018 Aug 8;2018:6984948
pubmed: 30159341
Nat Rev Clin Oncol. 2013 Aug;10(8):472-84
pubmed: 23836314
Signal Transduct Target Ther. 2019 Nov 13;4:47
pubmed: 31728212
Lung Cancer. 2017 Sep;111:176-181
pubmed: 28838390
J Clin Med. 2019 Jul 10;8(7):
pubmed: 31295929
Cancer Med. 2019 Dec;8(18):7669-7678
pubmed: 31692284
Clin Lung Cancer. 2018 Sep;19(5):410-417.e1
pubmed: 29859759
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
Lung Cancer. 2018 Apr;118:57-61
pubmed: 29572003
Eur J Cancer. 2019 Jan;106:144-159
pubmed: 30528799
Eur J Cancer. 2017 Apr;75:141-149
pubmed: 28222308
J Immunother Cancer. 2019 Oct 26;7(1):278
pubmed: 31655605
Ann Oncol. 2017 Aug 1;28(8):1996-2001
pubmed: 28459943
Cancer Sci. 2019 Aug;110(8):2348-2356
pubmed: 31222843
Ther Adv Med Oncol. 2018 Jan 18;10:1758834017749748
pubmed: 29383037
Oncotarget. 2016 Feb 9;7(6):7227-40
pubmed: 26811495
Transl Lung Cancer Res. 2018 Dec;7(6):661-667
pubmed: 30505710
Cancer Res. 2017 Mar 15;77(6):1322-1330
pubmed: 28031229
Ann Oncol. 2018 Jun 1;29(6):1417-1422
pubmed: 29659668
Nat Rev Cancer. 2019 Sep;19(9):495-509
pubmed: 31406302
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034
pubmed: 31506389
Oncoimmunology. 2018 Jan 29;7(5):e1424675
pubmed: 29721388
J Thorac Oncol. 2018 Sep;13(9):1248-1268
pubmed: 29885479
Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8
pubmed: 16247014
PLoS One. 2012;7(6):e40109
pubmed: 22768234
Sci Transl Med. 2014 May 28;6(238):238ra70
pubmed: 24871131
Int J Clin Oncol. 2018 Dec;23(6):1052-1059
pubmed: 29948239
Nature. 2018 Aug;560(7718):382-386
pubmed: 30089911
Cancer Cell. 2007 Jul;12(1):9-22
pubmed: 17613433
Nature. 2014 Nov 27;515(7528):568-71
pubmed: 25428505
Clin Cancer Res. 2018 Apr 15;24(8):1872-1880
pubmed: 29330207
J Thorac Dis. 2015 Mar;7(3):462-70
pubmed: 25922726
J Immunother Cancer. 2020 Jan;8(1):
pubmed: 31959728
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
Nat Rev Immunol. 2008 Jun;8(6):467-77
pubmed: 18500231
PLoS One. 2017 Jul 17;12(7):e0181125
pubmed: 28715437
Lancet Oncol. 2018 Sep;19(9):1180-1191
pubmed: 30120041
Clin Cancer Res. 2019 Aug 1;25(15):4691-4700
pubmed: 30988079
Oncoimmunology. 2018 Mar 6;7(7):e1438111
pubmed: 29900038
Int J Clin Oncol. 2020 May;25(5):801-809
pubmed: 32246277
Mol Cancer. 2018 Apr 12;17(1):81
pubmed: 29650000
Neoplasia. 2015 Nov;17(11):839-48
pubmed: 26678911
Cell. 2007 Jan 12;128(1):157-70
pubmed: 17218262
J Clin Oncol. 2019 Mar 1;37(7):537-546
pubmed: 30620668
Clin Lung Cancer. 2006 Jul;8(1):30-8
pubmed: 16870043
Cancer Sci. 2018 Oct;109(10):2998-3004
pubmed: 29999574
Nat Rev Cancer. 2009 Aug;9(8):563-75
pubmed: 19629071
Genomics. 1994 Mar 15;20(2):223-6
pubmed: 8020968
Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3
pubmed: 5279523
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Ann Oncol. 2016 Mar;27(3):409-16
pubmed: 26681673
Ann Oncol. 2019 Feb 1;30(2):281-289
pubmed: 30657853
Science. 1991 Aug 9;253(5020):665-9
pubmed: 1651563
J Clin Pathol. 2018 Mar;71(3):189-194
pubmed: 29097600
J Natl Cancer Inst. 2015 Feb 03;107(3):
pubmed: 25650315
Oncoimmunology. 2015 Nov 25;5(4):e1100788
pubmed: 27141381
Nat Genet. 2010 May;42(5):454-8
pubmed: 20400965
J Immunol. 2017 Feb 1;198(3):981-985
pubmed: 28115586
Nat Med. 2018 Sep;24(9):1441-1448
pubmed: 30082870
J Immunother Cancer. 2018 Nov 23;6(1):129
pubmed: 30470260
Nat Med. 1999 Jun;5(6):677-85
pubmed: 10371507
Science. 2016 Mar 25;351(6280):1463-9
pubmed: 26940869
J Immunol. 1999 May 1;162(9):5212-23
pubmed: 10227995
Br J Cancer. 2018 Mar 20;118(6):820-824
pubmed: 29509748
J Clin Invest. 2016 Jun 1;126(6):2334-40
pubmed: 27159395
J Virol. 2016 Apr 29;90(10):5059-5067
pubmed: 26962220
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Clin Cancer Res. 2017 Oct 1;23(19):5948-5958
pubmed: 28679765
Cancer Immunol Res. 2019 Jan;7(1):77-85
pubmed: 30425105
Cancers (Basel). 2019 Jun 17;11(6):
pubmed: 31212989
J Surg Res. 2011 May 15;167(2):207-10
pubmed: 19896677
Curr Opin Oncol. 2019 Jan;31(1):24-28
pubmed: 30418192
DNA Repair (Amst). 2013 Nov;12(11):954-63
pubmed: 24051051
J Immunother. 2020 Feb/Mar;43(2):57-66
pubmed: 31592989
Onco Targets Ther. 2013 Jul 10;6:869-75
pubmed: 23874109
Oncotarget. 2018 Apr 3;9(25):17554-17563
pubmed: 29707129
Cancer Cell. 2018 May 14;33(5):843-852.e4
pubmed: 29657128
Immunotherapy. 2016;8(4):479-88
pubmed: 26973128
Cancer Immunol Immunother. 2012 Jul;61(7):1019-31
pubmed: 22146893
Science. 1984 Mar 9;223(4640):1028-33
pubmed: 6320372
Lung Cancer. 2019 Jan;127:153-163
pubmed: 30642544
Cancer Biomark. 2018;22(3):467-476
pubmed: 29758930
J Immunother Cancer. 2019 Jul 10;7(1):173
pubmed: 31291995
Cell Mol Life Sci. 2019 Dec;76(23):4613-4633
pubmed: 31352532
Ann Oncol. 2016 Jan;27(1):147-53
pubmed: 26483045
Front Med (Lausanne). 2018 Dec 12;5:351
pubmed: 30631766
Eur J Cancer. 2016 Mar;55:7-14
pubmed: 26771872
Nat Commun. 2017 Oct 26;8(1):1145
pubmed: 29074968
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10388-92
pubmed: 12920180
PLoS One. 2013 May 28;8(5):e64816
pubmed: 23724098
N Engl J Med. 2018 May 31;378(22):2078-2092
pubmed: 29658856
Cancer Discov. 2015 Aug;5(8):860-77
pubmed: 26069186
Transl Lung Cancer Res. 2018 Dec;7(6):639-646
pubmed: 30505708
J Clin Invest. 2016 Apr 1;126(4):1216-23
pubmed: 26927673
Cancer Res. 2019 Mar 15;79(6):1214-1225
pubmed: 30541742
Clin Cancer Res. 2018 Aug 15;24(16):3857-3866
pubmed: 29716923
Oncoimmunology. 2018 Apr 20;7(8):e1452581
pubmed: 30221046
J Thorac Oncol. 2019 Apr;14(4):606-616
pubmed: 30605727
Nature. 2013 Aug 22;500(7463):415-21
pubmed: 23945592
Cancer Discov. 2016 Feb;6(2):202-16
pubmed: 26645196
Br J Cancer. 2019 Jan;120(1):57-62
pubmed: 30377342
PLoS One. 2019 Mar 27;14(3):e0214318
pubmed: 30917185
Cancer Immunol Immunother. 2019 Jul;68(7):1087-1094
pubmed: 31089757
Cell Rep. 2017 May 9;19(6):1189-1201
pubmed: 28494868
Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20410-5
pubmed: 19074257
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407
Ann Oncol. 2016 Feb;27(2):225-32
pubmed: 26578726
J Clin Oncol. 2018 Mar 1;36(7):633-641
pubmed: 29337640
Cell Immunol. 2020 Jan;347:104008
pubmed: 31733822
Immunotherapy. 2017 May;9(6):499-506
pubmed: 28472902
Am J Pathol. 2011 Jul;179(1):37-45
pubmed: 21703392
Ther Adv Med Oncol. 2019 Apr 16;11:1758835919839928
pubmed: 31019571
N Engl J Med. 2017 Jun 22;376(25):2415-2426
pubmed: 28636851
Oncogene. 2011 Sep 1;30(35):3784-91
pubmed: 21532627
JAMA Oncol. 2018 Feb 1;4(2):210-216
pubmed: 29270615
Lung Cancer. 2017 Apr;106:1-7
pubmed: 28285682
N Engl J Med. 2016 Nov 3;375(18):1767-1778
pubmed: 27806234
Lancet. 2019 May 4;393(10183):1819-1830
pubmed: 30955977
J Pathol Transl Med. 2019 Jul;53(4):199-206
pubmed: 31042863
Cancer Res. 2017 Jul 1;77(13):3540-3550
pubmed: 28487385
Crit Rev Oncol Hematol. 2019 Nov;143:148-152
pubmed: 31675543
Ann Oncol. 2018 Jan 1;29(1):193-199
pubmed: 29361135
Nat Rev Cancer. 2016 Feb;16(2):71-81
pubmed: 26822575
J Thorac Oncol. 2018 Aug;13(8):1217-1221
pubmed: 29654927
Eur J Cancer. 2017 Nov;86:349-357
pubmed: 29078173
Cell. 2006 Feb 10;124(3):471-84
pubmed: 16469695
Cancers (Basel). 2019 Dec 19;12(1):
pubmed: 31861557
Cancer Med. 2018 Sep;7(9):4509-4516
pubmed: 30039553
J Clin Med. 2019 Oct 01;8(10):
pubmed: 31581482